Table 3.
Features of pazopanib-induced hypertension in the 20 patients in which it developed
| Parameter | Value | Range |
|---|---|---|
| Change in systolic BP (mm Hg) | 8.2 [−3.7-18.4] | −54.6-26.3 |
| Change in diastolic BP (mm Hg) | 5.6 [0.4-11.4] | −8.3-18.2 |
| Maximal systolic BP (mm Hg) | 167.5 [159.5-186.5] | 148-195 |
| Maximal diastolic BP (mm Hg) | 96 [92-106.5] | 80-112 |
| Time until pazopanib-induced HTN (days) | 24.5 [14.5-53.5] | 7-641 |
| Antihypertensive dose increased or new agent added | 17 (85) | |
| No preexisting HTN | 6 (30) | |
| Class of antihypertensive started or intensified | ||
| ACEIs or ARBs | 12 (46) | |
| Beta-blockers | 3 (12) | |
| Calcium channel blockers | 7 (27) | |
| Diuretics | 1 (4) | |
| Others* | 3 (12) | |
BP blood pressure, HTN hypertension, n number, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
Data presented as a number with percent (%) or median [1st quartile-3rd quartile]
*Clonidine (n = 2) and hydralazine (n = 1)